These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24252161)

  • 1. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient.
    Graham A; Jaworski K
    Haemophilia; 2014 Mar; 20(2):226-9. PubMed ID: 24252161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 × 3 crossover trial.
    Seaman CD; Yabes JG; Lalama CM; Ragni MV
    Haemophilia; 2021 May; 27(3):351-357. PubMed ID: 33749970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
    J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A.
    Tiede A; Cid AR; Goldmann G; Jiménez-Yuste V; Pluta M; Lissitchkov T; May M; Matytsina I; Miljic P; Pabinger I; Persson P
    Thromb Haemost; 2020 Feb; 120(2):277-288. PubMed ID: 31887776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
    Collins PW; Blanchette VS; Fischer K; Björkman S; Oh M; Fritsch S; Schroth P; Spotts G; Astermark J; Ewenstein B;
    J Thromb Haemost; 2009 Mar; 7(3):413-20. PubMed ID: 19143924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
    Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
    Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
    J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
    Tegenge MA; Yang H; Forshee RA
    Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
    van Moort I; Preijers T; Hazendonk HCAM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Leebeek FWG; Meijer K; Mathôt RAA; Cnossen MH;
    Br J Clin Pharmacol; 2021 Jun; 87(6):2602-2613. PubMed ID: 33232535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.